Application Area includes but not limited to:
It can be used to conduct risk stratification among diabetes patients within a healthcare system/ insurance network. A risk indicator ranged from 1~10, can be assigned to each patient according to their predicted short-term/long-term cardiovascular risks. Thus, the BRAVO model could help the healthcare system/ insurance network to maximize its disease management program’s effectiveness by accurately targeting the high-risk population.
It can be used to estimate long-term benefit of achieving treatment goals (education at clinical settings).
COST EFFECTIVENESS ANALYSIS
It can be applied to conduct classic pharmacoeconomics evaluation, comparing the cost-effectiveness between alternative drugs/treatments.
It can be applied to conduct Policy/program evaluation, assessing the cost-effectiveness of diabetes-related policy/programs.
About BRAVO™ MODEL
bravo™ model compares to other diabetes models
BW and BMI
utility and cost
Publications and Presentations
- Shao, H., Yang, S., Fonseca, V., Stoecker, C., & Shi, L. (2019). Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation. PharmacoEconomics, 1-9
- Shao, H., Fonseca, V., Stoecker, C., Liu, S., & Shi, L. (2018). Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO). PharmacoEconomics, 36(9), 1125-1134.
- Shao, H., Yang, S., Fonseca, V., & Shi, L. (2018). Globalization Module for A Diabetes Progression Prediction Model: The Building, Relating, Acting, and Validating Outcomes (Bravo) Model. Value in Health, 21, S5.
- Shao, H., Yang, S., Fonseca, V., Ji, X., & Shi, L. (2018). Projecting Long-Term Diabetes Complications through a BRAVO-Based Mock Simulation for Promoting Diabetes Prevention Program (DPP). Diabetes. 67. 701-P. 10.2337/db18-701-P.
- Shao, H., Fonseca, V., Stoecker, C., & Shi, L. (2017, May). Updating Risk Engine For Diabetes Progression and Mortality in the United States: Internal Validation. Value in Health (Vol. 20, No. 5, pp. A162-A162)